AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15723977 — intervention group
Group type: COMPARATOR
Intervention: bare‐metal stents
Number of subjects: 238
Study 11928027 — intervention group
Group type: COMPARATOR
Intervention: Outpatient group (discharged after 4 hours)
Number of subjects: 80
Study 11928027 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient group (admitted overnight)
Number of subjects: 80
Study 9866070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsing centrifugation
Number of subjects: 10
Study 9866070 — intervention group
Group type: COMPARATOR
Intervention: Standard centrifugation
Number of subjects: 10
Study 7608322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration (2 mg)
Number of subjects: 0
Study 7608322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration (5 mg)
Number of subjects: 0
Study 7608322 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled administration (2 mg)
Number of subjects: 0
Study 7608322 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Intravenous, Oral, Inhaled)
Number of subjects: 0
Study 2231488 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 14
Study 2231488 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 14
Study 323443 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone, 0.01 mg/kg intramuscularly
Number of subjects: 20
Study 323443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30859302 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ROM
Number of subjects: 204
Study 30859302 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative laxity
Number of subjects: 204
Study 30859302 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative laxity
Number of subjects: 204
Study 30859302 — intervention group
Group type: COMPARATOR
Intervention: Balanced vs. unbalanced groups
Number of subjects: 204
Study 30859302 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laxity
Number of subjects: 204
Study 28588168 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid advancement group (15ml/kg/day for 1000-<1250g; 20ml/kg/day for 1250-<1500g)
Number of subjects: 95
Study 28588168 — intervention group
Group type: COMPARATOR
Intervention: Slow advancement group (10ml/kg/day for 1000-<1250g; 15ml/kg/day for 1250-<1500g)
Number of subjects: 95
Study 26419681 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Daikenchuto (TJ-100)
Number of subjects: 110
Study 26419681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 24124985 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualisation combined with health message (first-person perspective)
Number of subjects: 532
Study 24124985 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualisation combined with health message (third-person perspective)
Number of subjects: 532
Study 24124985 — intervention group
Group type: COMPARATOR
Intervention: Visualisation without health message
Number of subjects: 532
Study 24124985 — intervention group
Group type: COMPARATOR
Intervention: Health message only (no visualisation)
Number of subjects: 532
Study 24124985 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualisation (irrespective of perspective) with health message
Number of subjects: 532
Study 21083558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport-240
Number of subjects: 128
Study 21083558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 19185241 — intervention group
Group type: EXPERIMENTAL
Intervention: HumanOptics MC611MI microincision IOL
Number of subjects: 32
Study 19185241 — intervention group
Group type: COMPARATOR
Intervention: Alcon AcrySof MA60AC 3‐piece IOL
Number of subjects: 32
Study 19185241 — intervention group
Group type: COMPARATOR
Intervention: Control group (Alcon AcrySof MA60AC 3‐piece IOL)
Number of subjects: 32
Study 19185241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 32
Study 17335317 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (started at 25 mg/day, titrated to 400 mg/day or maximum tolerated dose)
Number of subjects: 38
Study 17335317 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 38
Study 17335317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15367052 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine plus 12 sessions of CBT
Number of subjects: 35
Study 15367052 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine only
Number of subjects: 35
Study 11583498 — intervention group
Group type: EXPERIMENTAL
Intervention: Home inflation of tissue expanders
Number of subjects: 23
Study 11583498 — intervention group
Group type: COMPARATOR
Intervention: Outpatient inflation of tissue expanders
Number of subjects: 23
Study 9523369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted DLCOsb values after applying corrections for VD, carbon dioxide, hemoglobin, and carboxyhemoglobin
Number of subjects: 1214
Study 9523369 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction for VD
Number of subjects: 1214
Study 9523369 — intervention group
Group type: EXPERIMENTAL
Intervention: All corrections considered
Number of subjects: 1214
Study 9523369 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction for Hb
Number of subjects: 1214
Study 1895265 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone intervention
Number of subjects: 439
Study 1895265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic intervention
Number of subjects: 439
Study 1895265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both phone and clinic intervention
Number of subjects: 439
Study 1895265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 439
Study 6762370 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐carnitine (1.2‐1.8 g/day)
Number of subjects: 43
Study 6762370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31362119 — intervention group
Group type: EXPERIMENTAL
Intervention: Double negative for HBV DNA and RNA at the end of treatment (evaluation cohort)
Number of subjects: 130
Study 31362119 — intervention group
Group type: COMPARATOR
Intervention: Positive for either HBV DNA or RNA at the end of treatment (evaluation cohort)
Number of subjects: 130
Study 31362119 — intervention group
Group type: EXPERIMENTAL
Intervention: Double negative for HBV DNA and RNA at the end of treatment (validation cohort)
Number of subjects: 130
Study 31362119 — intervention group
Group type: COMPARATOR
Intervention: Positive for either HBV DNA or RNA at the end of treatment (validation cohort)
Number of subjects: 130
Study 30699846 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3 g/day
Number of subjects: 80
Study 30699846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28342061 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab in combination with chlorambucil (GClb)
Number of subjects: 0
Study 28342061 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab in combination with chlorambucil (RClb)
Number of subjects: 0
Study 28342061 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil alone (Clb)
Number of subjects: 0
Study 27423373 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioural therapy (CBT‐E)
Number of subjects: 0
Study 27423373 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0
Study 27423373 — intervention group
Group type: COMPARATOR
Intervention: Enhanced cognitive behavioural therapy (CBT‐E) and Interpersonal psychotherapy (IPT)
Number of subjects: 0
Study 25591521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 300
Study 25591521 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300
Study 22909345 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 382
Study 20485039 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified maxillary protraction appliance (MMPA)
Number of subjects: 26
Study 20485039 — intervention group
Group type: COMPARATOR
Intervention: Bimaxillary surgery (BMS)
Number of subjects: 26
Study 18538401 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose verteporfin photodynamic therapy (PDT)
Number of subjects: 63
Study 18538401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 15800144 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPECT intervention (care management model with trained care managers providing algorithm-based recommendations and treatment adherence support over 18 months)
Number of subjects: 215
Study 15800144 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 215
Study 15800144 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPECT intervention
Number of subjects: 215
Study 12446281 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 8
Study 12446281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10559522 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 ml of red wine (30 g alcohol) per day for 2 weeks
Number of subjects: 7
Study 10559522 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 7
Study 10559522 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine
Number of subjects: 7
Study 10559522 — intervention group
Group type: EXPERIMENTAL
Intervention: Red grape juice
Number of subjects: 7
Study 9170760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment
Number of subjects: 94
Study 9170760 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 94
Study 7505360 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (20 mg)
Number of subjects: 8
Study 7505360 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg)
Number of subjects: 8
Study 7505360 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 8
Study 7505360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3083458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 3083458 — intervention group
Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 0
Study 3083458 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 0
Study 3083458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30085177 — intervention group
Group type: EXPERIMENTAL
Intervention: Allostatic load (AL) score
Number of subjects: 836
Study 26590199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Anesthetic Induction Patient Safety (PIPS) checklist embedded in Anesthesia Information Management System (AIMS)
Number of subjects: 38
Study 26590199 — intervention group
Group type: COMPARATOR
Intervention: No checklist
Number of subjects: 38
Study 26590199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Anesthetic Induction Patient Safety (PIPS) checklist
Number of subjects: 38
Study 25323030 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of school meals rich in fish, vegetables, and fibre
Number of subjects: 834
Study 25323030 — intervention group
Group type: COMPARATOR
Intervention: Usual packed lunch from home (control)
Number of subjects: 834
Study 22492382 — intervention group
Group type: EXPERIMENTAL
Intervention: RUCF (fortified soybean-maize-sorghum paste)
Number of subjects: 1383
Study 22492382 — intervention group
Group type: COMPARATOR
Intervention: UNIMIX (fortified corn soy blend porridge)
Number of subjects: 1383
Study 21744761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.0% (intravenous bolus 1.5 mg/kg followed by an infusion of 1.5 mg/kg/h)
Number of subjects: 60
Study 21744761 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 19089209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical method (Carisolv; MediTeam)
Number of subjects: 50
Study 19089209 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 50
Study 15953979 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention (verbal information on the Medicaid pharmacotherapy benefit)
Number of subjects: 608
Study 15953979 — intervention group
Group type: EXPERIMENTAL
Intervention: Self Help (verbal information plus self‐help information materials)
Number of subjects: 608
Study 15953979 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (verbal information, self‐help information, plus case management assistance)
Number of subjects: 608
Study 15953979 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 608
Study 11915973 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 424
Study 11915973 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 424
Study 10423024 — intervention group
Group type: EXPERIMENTAL
Intervention: Late menarche (>14 years)
Number of subjects: 169
Study 10423024 — intervention group
Group type: COMPARATOR
Intervention: Early menarche (<12 years)
Number of subjects: 169
Study 10423024 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for weight
Number of subjects: 169
Study 10423024 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 169
Study 7671177 — intervention group
Group type: EXPERIMENTAL
Intervention: Home program of aerobic training (intensity gradually increasing from 1.5 to 4.0 METs) for 8 weeks starting at discharge.
Number of subjects: 80
Study 7671177 — intervention group
Group type: COMPARATOR
Intervention: General guidelines for progressive increase of activity level (Control group).
Number of subjects: 80
Study 1954069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 14
Study 1954069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 14
Study 1954069 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (15 mg)
Number of subjects: 14
Study 7272163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroxazone 300 mg/day for 12 days
Number of subjects: 0
Study 7272163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroxazone 600 mg/day for 12 days
Number of subjects: 0
Study 7272163 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine 20 mg/day for 8 days
Number of subjects: 0
Study 7272163 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 50 mg/day for 12 days
Number of subjects: 0
Study 7272163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroxazone
Number of subjects: 0
Study 7272163 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 7272163 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 0
Study 7272163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroxazone 300 mg/day
Number of subjects: 0
Study 7272163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroxazone 600 mg/day
Number of subjects: 0
Study 30391759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Tranexamic Acid (TXA)
Number of subjects: 126
Study 30391759 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of Tranexamic Acid (TXA)
Number of subjects: 126
Study 30391759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 30391759 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 126
Study 28200045 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose regimen of Benzathine Penicillin G (2.4 million units)
Number of subjects: 64
Study 28200045 — intervention group
Group type: COMPARATOR
Intervention: 3-dose regimen of Benzathine Penicillin G
Number of subjects: 64
Study 25389044 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent Blue dye injection
Number of subjects: 40
Study 25389044 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study 25389044 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 24029053 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-[fluorine-18]fluoro-2-deoxy-(D)-glucose (FDG) PET scans in hyperthyroid patients
Number of subjects: 48
Study 24029053 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 participants)
Number of subjects: 48
Study 21334402 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D3 levels
Number of subjects: 189
Study 19326982 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐T MR imaging
Number of subjects: 26
Study 19326982 — intervention group
Group type: COMPARATOR
Intervention: 1.5‐T MR imaging
Number of subjects: 26
Study 17384435 — intervention group
Group type: EXPERIMENTAL
Intervention: LY518674 (25 microg)
Number of subjects: 613
Study 17384435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg)
Number of subjects: 613
Study 17384435 — intervention group
Group type: EXPERIMENTAL
Intervention: LY518674 (100 microg)
Number of subjects: 613
Study 17384435 — intervention group
Group type: EXPERIMENTAL
Intervention: LY518674 (50 microg)
Number of subjects: 613
Study 17384435 — intervention group
Group type: EXPERIMENTAL
Intervention: LY518674 (10 microg)
Number of subjects: 613
Study 17384435 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 or 40 mg) + LY518674
Number of subjects: 613
Study 17384435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 613
Study 17384435 — intervention group
Group type: EXPERIMENTAL
Intervention: LY518674 (50 microg and 100 microg)
Number of subjects: 613
Study 15163444 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg/day)
Number of subjects: 14
Study 15163444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11176963 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-431 (5, 10, 20, and 40 mg)
Number of subjects: 20
Study 11176963 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 20
Study 9483595 — intervention group
Group type: EXPERIMENTAL
Intervention: Air (Group A)
Number of subjects: 52
Study 9483595 — intervention group
Group type: COMPARATOR
Intervention: 65% N2O, oxygen and halothane (Group B)
Number of subjects: 52
Study 7915067 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg/1 min bolus, followed by 0.2 mg/kg/min infusion)
Number of subjects: 14
Study 7915067 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (0.025 mg/kg/3 min)
Number of subjects: 14
Study 2968052 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-hANP infusion at 10 pmol.kg‐1.min‐1 for 1 hour
Number of subjects: 14
Study 2968052 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (vehicle)
Number of subjects: 14
Study 2968052 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-hANP infusion
Number of subjects: 14
Study 2968052 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-hANP infusion in normal volunteers
Number of subjects: 14
Study 29778565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (400/600 kcal on two non-consecutive days)
Number of subjects: 112
Study 29778565 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction
Number of subjects: 112
Study 29778565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction
Number of subjects: 112
Study 28521967 — intervention group
Group type: EXPERIMENTAL
Intervention: +PD (with pterygomaxillary disjunction)
Number of subjects: 25
Study 28521967 — intervention group
Group type: COMPARATOR
Intervention: -PD (without pterygomaxillary disjunction)
Number of subjects: 25
Study 25166455 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized self-management (ISM) support
Number of subjects: 170
Study 25166455 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 170
Study 24074932 — intervention group
Group type: EXPERIMENTAL
Intervention: Passively scattered proton therapy (PSPT)
Number of subjects: 20
Study 24074932 — intervention group
Group type: COMPARATOR
Intervention: Intensity modulated photon therapy (IMRT)
Number of subjects: 20
Study 20675936 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-bisphosphonate treatment for Osteogenesis Imperfecta
Number of subjects: 0
Study 18794653 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 38
Study 18794653 — intervention group
Group type: COMPARATOR
Intervention: Sodium Valproate (VPA)
Number of subjects: 38
Study 16124952 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 16124952 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 0
Study 16124952 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin and UFH
Number of subjects: 0
Study 12667386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir phosphate, 75 mg twice daily for 5 days
Number of subjects: 478
Study 12667386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 12667386 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir phosphate and Placebo
Number of subjects: 478
Study 10665159 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided self-help
Number of subjects: 40
Study 10665159 — intervention group
Group type: COMPARATOR
Intervention: Unguided self-help
Number of subjects: 40
Study 8625237 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC (5-fluorouracil, doxorubicin, cyclophosphamide)
Number of subjects: 0
Study 8625237 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 0
Study 8625237 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC (5-fluorouracil, cyclophosphamide)
Number of subjects: 0
Study 8625237 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC and FTC
Number of subjects: 0
Study 1805068 — intervention group
Group type: EXPERIMENTAL
Intervention: Acediprol (sodium valproate)
Number of subjects: 37
Study 7408415 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (50 U intravenously)
Number of subjects: 8
Study 7408415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative doses of heparin
Number of subjects: 8
Study 7408415 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (400 U intravenously of Harris LO14)
Number of subjects: 8